New drug duo aims to fight kidney cancer without losing the kidney
NCT ID NCT07584733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a two-drug treatment (disitamab vedotin plus tislelizumab) for people with a rare, aggressive cancer of the upper urinary tract that has a specific marker (HER2-positive). The goal is to shrink the tumor so that the kidney can be saved, avoiding complete removal. About 50 adults will receive the drugs before deciding on surgery, with the main focus on keeping the kidney cancer-free for at least one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE HIGH-RISK UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ethics Committee of Shanghai Renji Hospital
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could spot bladder Cancer's return
- Can a tiny ultrasound probe see how deep a urinary tract tumor goes?
- Two-Drug combo aims to shrink upper tract bladder cancer before surgery
- Could a drug combo spare bladder cancer patients from surgery?
- Tiny camera could replace surgery for bladder cancer checks
- Pee test could replace needles for bladder cancer detection